Skip to main content

Table 3 FDG and FLT-PET imaging results

From: 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

PET measure FDG (N = 22) FLT (N = 27)
Mean (range)  
SUVmax (pre-therapy)
 All 3.0 (1.4–10.9) 3.0 (1.1–7.8)
 Ductal 3.1 (1.4–10.9) 3.5 (1.4–7.8)
 Lobular 3.0 (1.8–4.1) 1.6 (1.1–3.2)
SUVmax (post-therapy)
 All 2.5 (0.9–10.6) 2.0 (0.8–3.8)
 Ductal 2.5 (0.9–10.6) 2.2 (1.1–3.8)
 Lobular 2.3 (1.6–3.0) 1.3 (0.8–2.2)
SUVmax (percent change)
 All  −17% (−45 to 28%)  −26% (−77 to 7%)
 Ductal  −17% (−45 to 28%)  −30% (−77 to 7%)
 Lobular  −19% (−27 to −11%)  −15% (−33 to 1%)
SUVmax (unit change)
 All  −0.5 (−1.3 to 0.7)  −1.0 (−6.0 to 0.1)
 Ductal  −0.5 (−1.3 to 0.7)  −1.3 (−6.0 to 0.1)
 Lobular  −0.7 (−1.1 to -0.2)  −0.30 (−1.0 to 0.02)
  1. This table indicates the average uptake from both scans for FDG and FLT as well as the percent and unit change between pre- and post-therapy scans